These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 29762551)

  • 1. A pair of datasets for microRNA expression profiling to examine the use of careful study design for assigning arrays to samples.
    Qin LX; Huang HC; Villafania L; Cavatore M; Olvera N; Levine DA
    Sci Data; 2018 May; 5():180084. PubMed ID: 29762551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
    Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
    Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of gene expression profiles to stage concurrent endometrioid tumors of the endometrium and ovary.
    Guirguis A; Elishaev E; Oh SH; Tseng GC; Zorn K; DeLoia JA
    Gynecol Oncol; 2008 Feb; 108(2):370-6. PubMed ID: 18083218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blocking and randomization to improve molecular biomarker discovery.
    Qin LX; Zhou Q; Bogomolniy F; Villafania L; Olvera N; Cavatore M; Satagopan JM; Begg CB; Levine DA
    Clin Cancer Res; 2014 Jul; 20(13):3371-8. PubMed ID: 24788100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.
    Zou J; Yin F; Wang Q; Zhang W; Li L
    Int J Clin Exp Pathol; 2015; 8(6):6847-58. PubMed ID: 26261572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preprocessing Steps for Agilent MicroRNA Arrays: Does the Order Matter?
    Qin LX; Huang HC; Zhou Q
    Cancer Inform; 2014; 13(Suppl 4):105-9. PubMed ID: 26380547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Microarray analysis of endometrial carcinomas and mixed mullerian tumors reveals distinct gene expression profiles associated with different histologic types of uterine cancer.
    Maxwell GL; Chandramouli GV; Dainty L; Litzi TJ; Berchuck A; Barrett JC; Risinger JI
    Clin Cancer Res; 2005 Jun; 11(11):4056-66. PubMed ID: 15930340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cautionary Note on Using Cross-Validation for Molecular Classification.
    Qin LX; Huang HC; Begg CB
    J Clin Oncol; 2016 Nov; 34(32):3931-3938. PubMed ID: 27601553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA expression profiles in serous ovarian carcinoma.
    Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
    Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays.
    Wang Y; Barbacioru C; Hyland F; Xiao W; Hunkapiller KL; Blake J; Chan F; Gonzalez C; Zhang L; Samaha RR
    BMC Genomics; 2006 Mar; 7():59. PubMed ID: 16551369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of microRNA expression in serous ovarian carcinoma.
    Li Y; Yao L; Liu F; Hong J; Chen L; Zhang B; Zhang W
    Int J Mol Med; 2014 Aug; 34(2):491-8. PubMed ID: 24939816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
    Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
    Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Expression of microRNAs in endometrioid adenocarcinoma].
    Liu X; Xia W; Dai YM; Shao NS; Zhang WY
    Zhonghua Yi Xue Za Zhi; 2009 May; 89(19):1365-7. PubMed ID: 19615196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. cDNA microarray analysis and immunohistochemistry reveal a distinct molecular phenotype in serous endometrial cancer compared to endometrioid endometrial cancer.
    Chen Y; Yao Y; Zhang L; Li X; Wang Y; Zhao L; Wang J; Wang G; Shen D; Wei L; Zhao J
    Exp Mol Pathol; 2011 Aug; 91(1):373-84. PubMed ID: 21540026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic and prognostic significance of miRNA signatures in tissues and plasma of endometrioid endometrial carcinoma patients.
    Torres A; Torres K; Pesci A; Ceccaroni M; Paszkowski T; Cassandrini P; Zamboni G; Maciejewski R
    Int J Cancer; 2013 Apr; 132(7):1633-45. PubMed ID: 22987275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histologic type, organ of origin, and Wnt pathway status: effect on gene expression in ovarian and uterine carcinomas.
    Shedden KA; Kshirsagar MP; Schwartz DR; Wu R; Yu H; Misek DE; Hanash S; Katabuchi H; Ellenson LH; Fearon ER; Cho KR
    Clin Cancer Res; 2005 Mar; 11(6):2123-31. PubMed ID: 15788657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of microRNA-145, OCT4, and SOX2 in double primary endometrioid endometrial and ovarian carcinomas.
    Zhang R; Jiao J; Chu H; Yang H; Wang L; Gao N
    Histol Histopathol; 2018 Aug; 33(8):859-870. PubMed ID: 29569698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of Cell-Free Urine microRNAs Expression for the Use in Diagnosis of Ovarian and Endometrial Cancers. A Pilot Study.
    Záveský L; Jandáková E; Turyna R; Langmeierová L; Weinberger V; Záveská Drábková L; Hůlková M; Hořínek A; Dušková D; Feyereisl J; Minář L; Kohoutová M
    Pathol Oncol Res; 2015 Sep; 21(4):1027-35. PubMed ID: 25827090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
    Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
    Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.